Codexis (CDXS) Net Income towards Common Stockholders (2010 - 2026)
Codexis (CDXS) recorded quarterly Net Income towards Common Stockholders of -$8.7 million in Q1 2026, down 190.66% quarter-over-quarter from $9.6 million in Q4 2025, and up 57.93% on a YoY basis from -$5.5 million in Q1 2025.
Codexis (CDXS) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Codexis' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$8.7 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 57.93% year-over-year to -$8.7 million; the TTM figure through Mar 2026 stood at -$32.0 million (up 57.04% YoY), while the FY2025 annual figure was -$44.0 million, up 32.63% from the prior year.
- Net Income towards Common Stockholders was -$8.7 million for Q1 2026 at Codexis, down from $9.6 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $9.6 million in Q4 2025 to a low of -$34.9 million in Q3 2023.
- Historically, Net Income towards Common Stockholders has averaged -$13.4 million across 5 years, with a median of -$11.5 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders slumped 545.28% in 2022, then soared 192.53% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$12.6 million in 2022, then soared by 42.94% to -$7.2 million in 2023, then sank by 44.27% to -$10.4 million in 2024, then jumped by 192.53% to $9.6 million in 2025, then plunged by 190.66% to -$8.7 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$8.7 million (Q1 2026), $9.6 million (Q4 2025), and -$19.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Codexis | 236.00 Mn | 170.86 Mn | 13.18 Mn | -8.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.70 Mn |
| Dec 31, 2025 | 9.60 Mn |
| Sep 30, 2025 | -19.62 Mn |
| Jun 30, 2025 | -13.27 Mn |
| Mar 31, 2025 | -20.69 Mn |
| Dec 31, 2024 | -10.38 Mn |
| Sep 30, 2024 | -20.64 Mn |
| Jun 30, 2024 | -22.76 Mn |
| Mar 31, 2024 | -11.51 Mn |
| Dec 31, 2023 | -7.19 Mn |
| Sep 30, 2023 | -34.91 Mn |
| Jun 30, 2023 | -11.52 Mn |
| Mar 31, 2023 | -22.62 Mn |
| Dec 31, 2022 | -12.60 Mn |
| Sep 30, 2022 | -9.99 Mn |
| Jun 30, 2022 | -2.64 Mn |
| Mar 31, 2022 | -8.36 Mn |
| Dec 31, 2021 | -10.19 Mn |
| Sep 30, 2021 | 2.24 Mn |
| Jun 30, 2021 | -4.27 Mn |